Positive Animal Data Presented at EuroPCR Sets Stage for Advancing Neovasc's Tiara(TM) Transcatheter Mitral Valve into Human Trials

-Longer-Term Animal Data Suggests Tiara Device for the Transcatheter Treatment of Mitral Valve Disease Appears Safe and Well Tolerated

TSX Venture Exchange: NVC

PARIS and VANCOUVER, May 23, 2013 /CNW/ - Neovasc Inc. (TSXV: NVC), a developer of novel technologies to treat vascular disease, reported that positive animal data from its Tiara^TM program for the transcatheter treatment of mitral valve disease was presented today at EuroPCR 2013, the annual meeting of the European Association for Percutaneous Cardiovascular Interventions.

Neovasc Medical Director, Professor Shmuel Banai, MD, who is also an Associate Professor of Medicine and Cardiology at Tel Aviv University's Sackler School of Medicine and Director of Interventional Cardiology at Tel Aviv Medical Center, presented data on long-term implantation of the Tiara mitral replacement valve in an animal model of mitral regurgitation (MR).

The data shows that all seven animals implanted with the Tiara device were thriving at the end of the 150-day study, with no signs of inflammation or other adverse reactions to the implanted valve.  The Tiara device was well incorporated into the native anatomy and anchored in place with no evidence of migration. At 150 days, valve leaflets were functioning well with no significant degradation in hydrodynamic performance or calcification.  In all of the animals, left ventricular outflow was unimpeded, and the aortic valve continued to function normally.

Professor Banai commented, "We are encouraged by these results showing that the Tiara mitral valve replacement device was well tolerated for the full 150 days of this study.  Transcatheter mitral valve replacement involves many technical challenges, but a growing body of animal data suggests that the Tiara device is safe and performs very well after implantation.  We look forward to the opportunity to test the Tiara device in human subjects starting later this year or early in 2014."

The Tiara program is a novel solution to treat mitral valve regurgitation, a serious and poorly served condition that requires development of highly specialized devices to address the complex mitral anatomy.  Mitral regurgitation is often severe and can lead to heart failure and death, but conventional surgical treatments are only appropriate for a small percentage of patients. Approximately four million patients in the US alone are estimated to have MR.

Neovasc CEO Alexei Marko commented, "We are making excellent progress in the development of our Tiara technology for the transcatheter treatment of mitral valve disease, and we are pleased to share our promising longer-term animal results with leading interventional cardiologists at EuroPCR.  If our preclinical work continues to go well, we hope to achieve the first implantations in humans in late 2013 or early 2014."

Neovasc's Tiara technology is featured in four scientific sessions at EuroPCR 2013.

About EuroPCR
EuroPCR is the official annual meeting of the European Association of Percutaneous Cardiovascular Interventions.  EuroPCR 2013 is being held in Paris, France, May 21-24, 2013. For more information, visit www.europcr.com.

About Neovasc Inc.
Neovasc Inc. is a specialty medical device company that develops, manufactures and markets products for the rapidly growing global cardiovascular marketplace.  Its products include the Neovasc Reducer™ for the treatment of refractory angina and the Tiara™ transcatheter mitral valve replacement device in development for the treatment of mitral regurgitation.  In addition, Neovasc's advanced biological tissue products are widely used as key components in a variety of third-party medical products, such as transcatheter heart valves.  For more information, visit: www.neovasc.com.

Statements contained herein that are not based on historical or current fact, including without limitation statements containing the words "anticipates," "believes," "may," "continues," "estimates," "expects," and "will" and words of similar import, constitute "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, among others, the following: general economic and business conditions, both nationally and in the regions in which the Company operates; history of losses and lack of and uncertainty of revenues, ability to obtain required financing, receipt of regulatory approval of product candidates, ability to properly integrate newly acquired businesses, technology changes; competition; changes in business strategy or development plans; the ability to attract and retain qualified personnel; existing governmental regulations and changes in, or the failure to comply with, governmental regulations; liability and other claims asserted against the Company; and other factors referenced in the Company's filings with Canadian securities regulators. Although the Company believes that expectations conveyed by the forward-looking statements are reasonable based on the information available to it on the date such statements were made, no assurances can be given as to the future results, approvals or achievements. Given these uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. The Company does not assume the obligation to update any forward-looking statements except as otherwise required by applicable law.

SOURCE: Neovasc Inc.

Corporate contact:
Neovasc Inc.
Chris Clark
[phone]

U.S. media & investor contact:
BLL Partners, LLC
Barbara Lindeim
[phone]
[email protected]